Lynparza Maintenance for Ovarian Cancer Takes No Toll on Quality of Life, Study Shows

Lynparza Maintenance for Ovarian Cancer Takes No Toll on Quality of Life, Study Shows
Ovarian cancer patients who responded to platinum-based chemotherapy after failing at least one prior treatment may take Lynparza (olaparib) as maintenance therapy without worrying about their quality of life, a new study shows. The treatment is already approved for preventing disease progression or a relapse, and additional analysis shows that quality of life is not affected. If anything, patients experience meaningful benefits, researchers say. The study, “Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial,” was published in The Lancet Oncology. The SOLO-1 (NCT01844986) and SOLO-2 (NCT01874353) Phase 3 studies have shown that women with BRCA-mutated ovar
Subscribe or to access all post and page content.